MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells.
Botta C et al. Leukemia. 2017 Nov 21. doi: 10.1038/leu.2017.336. [Epub ahead of print].

Protein arginine methyltransferase 5 (PRMT5) has prognostic relevance and is a druggable target in multiple myeloma.
Gullà A et al.Leukemia. 2017 Nov 21. doi: 10.1038/leu.2017.334. [Epub ahead of print].

Comprehensive molecular profiling of 718 Multiple Myelomas reveals significant differences in mutation frequencies between African and European descent cases.
Manojlovic Z et al. PLoS Genet. 2017 Nov 22;13(11):e1007087. doi: 10.1371/journal.pgen.1007087. eCollection 2017 Nov.

Anti-cancer effects of Staphylococcal Enterotoxin type B on U266 cells co-cultured with Mesenchymal Stem Cells.
Ejtehadifar M et al. Microb Pathog. 2017 Nov 20. pii: S0882-4010(17)31375-X. doi: 10.1016/j.micpath.2017.11.024. [Epub ahead of print].

The Active Conformation of Integrin β7 May Be a Multiple Myeloma Target.
[No authors listed].Cancer Discov. 2017 Nov 17. doi: 10.1158/2159-8290.CD-RW2017-218. [Epub ahead of print].

Recombinant immunotoxins targeting B-cell maturation antigen are cytotoxic to myeloma cell lines and myeloma cells from patients.
Bera TK et al. Leukemia. 2017 Nov 17. doi: 10.1038/leu.2017.315. [Epub ahead of print].

Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a Cereblon-independent manner.
Dimopoulos K et al. Mol Oncol. 2017 Nov 11. doi: 10.1002/1878-0261.12157. [Epub ahead of print].

Human myeloma IgG4 reveals relatively rigid asymmetric Y-like structure with different conformational stability of CH2 domains.
Tischenko VM et al. Mol Immunol. 2017 Dec;92:199-210. doi: 10.1016/j.molimm.2017.10.014. Epub 2017 Nov 7.

Maternal embryonic leucine zipper kinase is a novel target for proliferation associated high-risk myeloma.
Bolomsky A et al. Haematologica. 2017 Nov 9. pii: haematol.2017.172973. doi: 10.3324/haematol.2017.172973. [Epub ahead of print].

Comparative Analysis of Quantitative Parameters of Expression of the Retinoic Acid Nuclear Receptor RARα Gene and APE1/YB-1/MDR1 Pattern Genes in Patients with Newly Detected Multiple Myeloma.
Kalitin NN et al. Bull Exp Biol Med. 2017 Nov;164(1):90-94. doi: 10.1007/s10517-017-3931-7. Epub 2017 Nov 9.

The activated conformation of integrin β7 is a novel multiple myeloma-specific target for CAR T cell therapy.
Hosen N et al. Nat Med. 2017 Nov 6. doi: 10.1038/nm.4431. [Epub ahead of print].

Combination of a novel HDAC 6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma.
Ray A et al. Leukemia. 2017 Nov 6. doi: 10.1038/leu.2017.322. [Epub ahead of print].

BAFF is involved in macrophage-induced bortezomib resistance in myeloma.
Chen J et al. Cell Death Dis. 2017 Nov 2;8(11):e3161. doi: 10.1038/cddis.2017.533.

Identification and characterization of HLA-A24 specific XBP1, CD138 (Syndecan-1), and CS1 (SLAMF7) peptides inducing antigens-specific memory cytotoxic T lymphocytes targeting multiple myeloma.
Bae J et al. Leukemia. 2017 Nov 1. doi: 10.1038/leu.2017.316. [Epub ahead of print].

SLAMF7-CAR T-cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes.
Gogishvili T et al. Blood. 2017 Oct 31. pii: blood-2017-04-778423. doi: 10.1182/blood-2017-04-778423. [Epub ahead of print].

Effects of Histone Deacetylase Inhibitor Panobinostat (LBH589) on Bone Marrow Mononuclear Cells of Relapsed or Refractory Multiple MyelomaPatients and Its Mechanisms.
Ma Y et al. Med Sci Monit. 2017 Oct 29;23:5150-5157.